← Newsroom
2019 · 05RegisterPress Releases

Oral portfolio broadened across therapeutic classes

Ergopharm's oral register has broadened beyond its original class, adding tablet products whose pharmacology, handling and testing requirements differ substantially from what came before.

Diversity in a register is not free. A low-dose tablet raises content-uniformity questions that a higher-strength product does not; a film-coated tablet adds coating process controls and a different dissolution profile; a hormone product brings its own cleaning and containment considerations. Each addition was assessed against the existing equipment train before it was accepted.

A register grows one product at a time and one cleaning validation at a time.

The analytical consequence was equally real: new methods, new reference standards, new impurity profiles to characterise against ICH Q3B thresholds, and new stability studies begun from scratch.

Every product entering the register carries the same documentation set — specification, method validation, stability programme, serialised pack layout — under a single controlled reference.

Key facts

Added
Tablet products across differing pharmacological classes
Assessed
Fit to the existing equipment train and cleaning bracket
Analytical
New methods, standards, impurity profiles, stability
Documentation
One controlled reference per monograph